FDA supports tighter restrictions on hydrocodone
WASHINGTON — The Food and Drug Administration is recommending tighter restrictions on prescription medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the United States.
In a major policy shift, the agency said in an online notice on Thursday that hydrocodone-containing drugs should be subject to the same restrictions as other narcotic drugs such as oxycodone and morphine.
More than a decade has passed since the Drug Enforcement Agency asked the FDA to reclassify hydrocodone so that it would be subject to the same restrictions as other opioid drugs. The FDA did not issue a formal announcement about its decision, which has long been sought by many patient advocates, doctors and lawmakers.
In early December, the FDA says it will formally request that hydrocodone be classified as a Schedule II drug, limiting who can write a prescription and how many times it can be refilled.
Show commenting policy
TribLive commenting policy
- Surge in small drones making airline pilots nervous
- Boston airport’s ‘naked man’ remains behind bars
- Test vaccine to fight Ebola promising
- House ethics panel defers campaign finance investigation of New York Rep. Grimm
- Many older people silently harbor gene mutation that could start them on the path to blood cancer
- Liberal Supreme Court Justice Ginsburg has stent placed in heart artery
- Obama’s immigration actions neglect business pleas
- Fewer adults smoking, U.S. survey finds
- Ferguson testimony filled with variations
- Obama administration announces plan to limit smog-forming ozone
- Fissures begin to emerge among Dems